SN1 N Stock Overview
Develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Smith & Nephew plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£290.15 |
| 52 Week High | UK£290.15 |
| 52 Week Low | UK£199.78 |
| Beta | 0.70 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -34.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| SN1 N | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how SN1 N performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how SN1 N performed against the MX Market.
Price Volatility
| SN1 N volatility | |
|---|---|
| SN1 N Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: SN1 N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine SN1 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1856 | 18,000 | Deepak Nath | www.smith-nephew.com |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Smith & Nephew plc Fundamentals Summary
| SN1 N fundamental statistics | |
|---|---|
| Market cap | Mex$226.93b |
| Earnings (TTM) | Mex$6.29b |
| Revenue (TTM) | Mex$116.32b |
36.1x
P/E Ratio2.0x
P/S RatioIs SN1 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SN1 N income statement (TTM) | |
|---|---|
| Revenue | US$5.64b |
| Cost of Revenue | US$1.67b |
| Gross Profit | US$3.97b |
| Other Expenses | US$3.66b |
| Earnings | US$305.00m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 70.33% |
| Net Profit Margin | 5.41% |
| Debt/Equity Ratio | 66.7% |
How did SN1 N perform over the long term?
See historical performance and comparison